RCT | Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson’s disease.

Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson’s disease: a randomised, double-blind, active-controlled, phase 3 trial – The Lancet Neurology (link to abstract – $ for full-text)

Commentary: Continuous Subcutaneous Carbidopa/Levodopa Demonstrates Benefits in Parkinson Disease Motor Fluctuations, OFF Time – Neurology Live

Commentary on Twitter

In a phase 3, randomised controlled trial, Michael Soileau and colleagues aimed to assess the safety and efficacy of a soluble formulation of levodopa and carbidopa in patients with advanced Parkinson's disease. Read the results at: https://t.co/9G8S01juSC pic.twitter.com/0SG0oTe8na

— The Lancet Neurology (@TheLancetNeuro) November 17, 2022